HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

RPID

Rapid Micro Biosystems, Inc. (NASDAQ)

Healthcare — Medical Devices

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

None 3 analysts
$2.06
$-0.04 (-1.90%)
Target: $6.67 (223.6%)
Sign in to add RPID to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$85.20M
P/E Ratio (TTM)-
Forward P/E-2.16
EPS (TTM)$-1.10
Dividend Yield-
Profit Margin-145.81%
Revenue Growth11.10%
ROE-116.74%
Debt/Equity116.24
Recommendation None
Analyst Target$6.67
Analysts3
Indexes NASDAQ

Technical Indicators

RSI (14)35.7
Beta1.46
SMA 20-
SMA 40-
52-Week High$4.94
52-Week Low$1.66
50-Day Avg$2.07
200-Day Avg$3.08
Avg Volume180.0K
Volume115.8K

Performance Analysis

NEUTRAL

RPID presents a mixed picture with both positive and negative indicators.

~ Trading at 12% of its 52-week range.
~ RSI at 35.7 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 11.1% year-over-year.
- Operating at a loss with -145.8% margin.
~ Wall Street consensus is "none" from 3 analysts.
+ Average analyst target of $6.67 implies 223.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:29 UTC

Back to Screener Export Report